SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-035854
Filing Date
2024-08-08
Accepted
2024-08-08 06:54:54
Documents
20
Period of Report
2024-08-08
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20240808.htm   iXBRL 8-K 28292
2 EX-99.1 pressrelease-2q24financi.htm EX-99.1 21285
6 pressrelease-2q24financi001.jpg GRAPHIC 225049
7 pressrelease-2q24financi002.jpg GRAPHIC 254927
8 pressrelease-2q24financi003.jpg GRAPHIC 234198
9 pressrelease-2q24financi004.jpg GRAPHIC 295000
10 pressrelease-2q24financi005.jpg GRAPHIC 227690
11 pressrelease-2q24financi006.jpg GRAPHIC 163713
  Complete submission text file 0001628280-24-035854.txt   2116500

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20240808.xsd EX-101.SCH 1922
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20240808_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20240808_pre.xml EX-101.PRE 13060
22 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20240808_htm.xml XML 2833
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 241185925
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)